Enhanced susceptibility of adriamycin-treated human renal cell carcinoma cells to lysis by peripheral blood lymphocytes and tumor infiltrating lymphocytes

Oncology Reports

Volumn 18, Issue 2, 2007, Pages 353-359

  Wu, Xiu Xian ^a   Zeng, Y ^a   Jin, X H ^a   Kakehi, Y ^a  

^a KAGAWA UNIVERSITY   (Japan)

Author keywords

Adriamycin; Immunotherapy; Peripheral blood lymphocytes; Renal cell carcinoma; Tumor infiltrating lymphocytes

Indexed keywords

ANTINEOPLASTIC ANTIBIOTIC; DOXORUBICIN; FAS ANTIGEN; FAS LIGAND; HLA ANTIGEN; INTERCELLULAR ADHESION MOLECULE 1; LYMPHOCYTE FUNCTION ASSOCIATED ANTIGEN 3; MONOCLONAL ANTIBODY; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND;

ARTICLE; CELL CULTURE; CELL SURVIVAL; CYTOTOXICITY; DRUG EFFECT; FLOW CYTOMETRY; HUMAN; IMMUNOLOGY; KIDNEY CARCINOMA; KIDNEY TUMOR; LYMPHOCYTE; METABOLISM; PATHOLOGY; TUMOR ASSOCIATED LEUKOCYTE; TUMOR CELL LINE;

ANTIBIOTICS, ANTINEOPLASTIC; ANTIBODIES, MONOCLONAL; ANTIGENS, CD58; ANTIGENS, CD95; CARCINOMA, RENAL CELL; CELL LINE, TUMOR; CELL SURVIVAL; CYTOTOXICITY, IMMUNOLOGIC; DOXORUBICIN; FAS LIGAND PROTEIN; FLOW CYTOMETRY; HLA ANTIGENS; HUMANS; INTERCELLULAR ADHESION MOLECULE-1; KIDNEY NEOPLASMS; LYMPHOCYTES; LYMPHOCYTES, TUMOR-INFILTRATING; TNF-RELATED APOPTOSIS-INDUCING LIGAND; TUMOR CELLS, CULTURED;

EID: 34548536950     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.18.2.353     Document Type: Article

References (23)

1. Hersh EM: Immunosuppressive agents. In: Antineoplastic and Immuno-suppressive Agents I. Sartorelli AC and Johns DG (eds). Springer-Verlag, New York, pp577-617, 1974.
2. Ehrke MJ and Mihich E: Immunoregulation by cancer chemotherapeutic agents. In: The Reticuloendothelial System: A Comprehensive Treatise. Hadder JW and Szentivanyi A (eds). Vol. 8, Plenum Press, New York, pp309-347, 1985.
3. Stoychkov JM, Sclutz RM, Chirigos MA, Pavlidis NA and Goldin A: Effect of adriamycin and cyclophosphamide treatment on induction of macrophage cytotoxic function in mice. Cancer Res 39: 3014-3017, 1997.
4. Orsini F, Pavelic Z and Mihich E: Increased primary cell mediated immunity in culture subsequent to adriamycin or daunorubicin treatment of spleen donor mice. Cancer Res 37: 1719-1726, 1997.
5. Santoni A, Riccardi C and Sorci V: Effects of adriamycin on the sensitivity of mouse natural killer cells. J Immunol 124: 2329-2335, 1980. (Pubitemid 10113327)
6. Mace K, Mayhew E and Mihich E: Alterations in murine host defense functions by Adriamycin, liposomes, or liposome-encapsulated adriamycin. Cancer Res 48: 130-136 1988. (Pubitemid 18030341)
7. Mizutani Y, Yoshida O and Miki T: Adriamycin-mediated potentiation of cytotoxicity against freshly isolated bladder cancer cells by autologous non-activated peripheral blood lymphocytes and tumor infiltrating lymphocytes. J Urol 162: 2170-2175, 1999.
8. Gautam SC, Chikkala NF, Ganapathi R and Hamilton TA: Combination therapy with adriamycin and interleukin 2 augments immunity against murine renal cell carcinoma. Cancer Res 51: 6133-6137, 1991.
9. Liu CC, Young LH and Young JD: Lymphocyte-mediated cytolysis and disease. N Engl J Med 335: 1651-1659, 1996
10. Wingren AG, Parra E, Varga M, et al: T cell activation pathways: B7, LFA-3, and ICAM-1 shape unique T cell profiles. Crit Rev Immunol 15: 235-253, 1995. (Pubitemid 26259130)
11. Omari KI and Dorovini-Zis K: Expression and function of lymphocyte function associated antigen-3 (LFA-3) at the bloodbrain barrier. Cell Mol Biol 45: 25-35, 1999.
12. Parra E, Wingren AG, Hedlund G, Kalland T and Dohlsten M: The role of B7-1 and LFA-3 in costimulation of CD8+ T cells. J Immunol 158: 637-642, 1997. (Pubitemid 127492640)
13. Belldegrun A, Muul LM and Rosenberg SA: Interleukin 2 expanded tumor-infiltrating lymphocytes in human renal cell cancer: isolation, characterization, and antitumor activity. Cancer Res 48: 206-214, 1998.
14. Wu XX, Mizutani Y, Kakehi Y, Yoshida O and Ogawa O: Enhancement of Fas-mediated apoptosis in renal cell carcinoma cells. Cancer Res 60: 2912-2918, 2000.
15. Mizutani Y, Bonavida B, Nio Y and Yoshida O: Enhanced susceptibility of cis-diamminedichloroplatinum-treated K562 cells to lysis by peripheral blood lymphocytes and lymphokine activated killer cells. Cancer 71: 1313-1321, 1993. (Pubitemid 23054925)
16. Wu XX, Kakehi Y, Mizutani Y, et al: Enhancement of TRAIL/Apo2L-mediated apoptosis by adriamycin through inducing DR4 and DR5 in renal cell carcinoma cells. Int J Cancer 104: 409-417, 2003. (Pubitemid 36323909)
17. Brittenden J, Heys SD, Ross J and Eremin O: Natural killer cells and cancer. Cancer 77: 1226-1243, 1996. (Pubitemid 26102319)
18. Ishihata R, Ejiri Y, Okubo M, Ohara M and Kasukawa R: Enhancement of lymphokine-activated killer cell cytotoxicity implicated in the increased expression of surface adhesion molecules on tumor cells treated with anticancer agents. Cancer Invest 14: 427-434, 1996. (Pubitemid 26338207)
19. Rivoltini L, Cattoretti G, Arienti F, et al: The high lysability by LAK cells of colon-carcinoma cells resistant to doxorubicin is associated with a high expression of ICAM-1, LFA-3, NCA and a less-differentiated phenotype. Int J Cancer 47: 746-754, 1991.
20. Marshall JL, Gulley JL, Arlen PM, et al: A Phase I study of sequential vaccinations with fowlpox-CEA (6D)-TRICOM alone and sequentially with vaccinia-CEA (6D)-TRICOM, with and without granulocyte-macrophage colony-stimulating factor, in patients with carcinogenic antigen-expressing carcinomas. J Clin Oncol 23: 720-731, 2005. (Pubitemid 46224171)
21. Ziegler-Heitbrock HWL, Erhardt J and Riethmuller G: Treatment of fresh human leukaemia cells with actinomycin D enhances their lysability by natural killer cells. Br J Cancer 48: 507-514, 1983. (Pubitemid 13021652)
22. Kayagaki N, Yamaguchi N, Nakayama M, et al: Expression and function of TNF-related apoptosis-inducing ligand on murine activated NK cells. J Immunol 163: 1906-1913, 1999. (Pubitemid 29382191)
23. Griffith TS, Wiley SR, Kubin MZ, Sedger LM, Maliszewski CR and Fanger NA: Monocyte-mediated tumoricidal activity via the tumor necrosis factor-related cytokine, TRAIL. J Exp Med 189: 1343-1354, 1999.